Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2019-11-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle raised funds for cash management, detailing purchases and redemptions of financial products such as bank wealth management products and structured deposits. It includes specific dates, amounts, and yields but does not present comprehensive financial statements or analysis typical of an interim or annual report. The document is relatively short (2386 characters) and serves as an update on financing activities related to idle raised funds. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP.
2019-11-01 Chinese
关于控股子公司完成医疗器械经营许可证变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Zhengzhou Antu Bioengineering Co., Ltd. regarding the completion of a change in the medical device business license registration for its controlling subsidiary. It details the change in warehouse address and business scope but does not contain financial data, management discussion, or regulatory certifications. The document is short (649 characters) and serves as a formal notification of a regulatory or operational update rather than a financial report or detailed management information. It does not fit into categories like Annual Report, Interim Report, or Management Reports. It is not a certification or officer attestation. The content aligns best with a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-10-29 Chinese
安图生物：招商证券股份有限公司关于郑州安图生物工程股份有限公司新增募集资金投资项目实施地点的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the addition of implementation locations for a fundraising investment project by Zhengzhou Antu Bioengineering Co., Ltd. It discusses the use of raised funds, project details, compliance with regulations, and approvals by the board and supervisory committee. The document does not contain financial statements or detailed financial data but is an official opinion related to the use of raised funds and project implementation. It is not an annual report, interim report, earnings release, or any direct financial report. It is also not a simple announcement of a report publication but a regulatory compliance and verification document. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2019-10-28 Chinese
安图生物关于新增募集资金投资项目实施地点的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the addition of implementation locations for projects funded by newly raised capital. It details the use of funds raised through convertible bonds, the adjustment of project locations, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but focuses on the update about the use of raised funds and project implementation locations. It is not a full financial report, earnings release, or management discussion. The document is relatively short (2488 characters) and serves as an official announcement about capital use and project location changes related to fundraising. Therefore, it fits best under Capital/Financing Update (CAP).
2019-10-28 Chinese
2019年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2019 年第三季度报告" which translates to "2019 Third Quarter Report." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2019. The report is unaudited as stated in the text. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2019
2019-10-28 Chinese
安图生物第三届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhengzhou Antu Biological Engineering Co., Ltd. regarding the review and approval of the company's 2019 third quarter report and an investment project location. It states that the Supervisory Board has reviewed and approved the 2019 Q3 report but does not contain the report itself or detailed financial data. The document is short (896 characters) and refers readers to the Shanghai Stock Exchange website for the full report. This fits the pattern of a Regulatory Filing (RNS) as it is an official announcement related to regulatory compliance and board resolutions, not the full quarterly report itself.
2019-10-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.